Project Grant R01HL185953
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University $163,160 on February 10, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize Fontan creation and failing Fontan ventricular assist device (VAD) implementation using patient-specific computational flow modeling and ex-vivo 4D-flow MRI cardiac simulation. The recipient will develop and validate patient-specific computational models testing hepatic flow distributions...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $105,476 for a Project Grant (CFDA 93.837, Cardiovascular Diseases Research) on January 25, 2027. The award funds research addressing two critical shortcomings in the current donor heart allocation system. The project develops data-driven policy solutions to improve the prioritization of candidates with durable left ventricular assist devices (LVADs), which extend time on mechanical support but are...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $163,160 on February 12, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize neoaortic valve biomechanics in the Ross procedure for congenital aortic valve disease. The research addresses durability limitations of the Ross procedure, in which a patient's healthy pulmonic valve is translocated to the aortic position. While the procedure offers a living valve replacement...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $410,449 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning August 1, 2025, with a completion date of July 31, 2027. This grant supports the development of novel synthetic biology strategies to enhance cell-based therapies for peripheral arterial disease (PAD), a condition affecting over 8 million Americans. The research will...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals $193,055 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support Dr. Vy Ho's transition to an independent surgeon-informaticist specializing in abdominal aortic aneurysm diagnosis, surveillance, and treatment. The award funds formal training in computer vision for cardiovascular risk prediction, risk factors for abdominal aortic aneurysms in underrepresented patient...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $1,541,206 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify druggable targets for cancer therapy-induced cardiotoxicity. The research characterizes proteasome inhibitor-induced cardiovascular toxicity through three aims. Aim 1 profiles cell type-specific cytotoxicity using patient-specific induced pluripotent stem cell-derived cardiomyocytes and endothelial...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $154,442 in project grant funding on August 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on mechanotransduction in smooth muscle cell dedifferentiation in peripheral artery disease. The research investigates how cells convert mechanical stimuli into biochemical signals and how impaired mechanotransduction contributes to smooth muscle cell dysfunction and...
The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $737,415 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the association between hospital market competition and inappropriate vascular surgical care in older adults. The recipient will conduct a research study analyzing overtreatment patterns in two conditions: abdominal aortic aneurysm (AAA) repair at small sizes not supported by clinical guidelines, and tibial interventions for claudication, an early presentation of peripheral artery disease. The study will pool data from the Vascular Quality Initiative linked to Medicare and Veterans Health Administration records to examine whether market competition at a granular level correlates with higher rates of inappropriate AAA and peripheral artery disease care. The hypothesis underlying the work is that competition among surgeons combined with fee-for-service payment models creates incentives to perform vascular surgery earlier than clinically recommended, potentially causing harm through increased costs and unnecessary interventions with high re-intervention rates. Performance will occur in Palo Alto, California, with a period of performance through May 31, 2031. This is a Project Grant, a standard assistance type under the NHLBI's competitive research program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/28/26 | ||
| Not listed | $737.4k | 8/26/26 |